Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer

Valeria Pecci, Fabiola Troisi, Aurora Aiello, Sara De Martino, Angela Carlino, Vincenzo Fiorentino, Cristian Ripoli, Dante Rotili, Francesco Pierconti, Maurizio Martini, Manuela Porru, Francesco Pinto, Antonello Mai, Pier Francesco Bassi, Claudio Grassi, Carlo Gaetano, Alfredo Pontecorvi, Lidia Strigari, Antonella Farsetti, Simona NanniCancer 2024 · DOI

This research paper, published in Cancer Cell International, explores a specific molecular "circuitry" that drives metastasis in prostate cancer and demonstrates how a targeted epigenetic drug can break that circuit to slow disease progression.

TL;DR

Researchers have identified that the long non-coding RNA H19 acts as a master regulator of cell adhesion; when H19 levels drop, prostate cancer cells form aggressive, "cohesive" clusters that metastasize more effectively. The study demonstrates that the epidrug GSK-J4 can disrupt this process by inhibiting histone demethylases, successfully reducing tumor growth and metastatic spread in both mouse models and patient-derived tissue slices.

What Problem Does This Paper Address?

Prostate cancer (PCa) is a leading cause of cancer-related death in men, primarily when it progresses to a metastatic stage that is often resistant to standard hormone therapies. Traditionally, metastasis is thought to occur via "Epithelial-to-Mesenchymal Transition" (EMT), where cells lose their stickiness to break away.

However, there is an alternative, highly aggressive mechanism called the cohesive metastatic phenotype. In this scenario, cancer cells travel in clusters, maintaining their adhesion to one another. This study investigates the role of a long non-coding RNA (lncRNA) called H19 in this process. The authors previously found that low levels of H19 (triggered by factors like hypoxia or estrogen) actually increase the expression of adhesion molecules like E-cadherin and $\beta$4 integrin, promoting these dangerous clusters. The challenge addressed here is proving this "circuitry" exists in vivo and finding a way to target it pharmacologically.

Methods

The authors employed a multi-scale experimental approach:

  • Cell Engineering: They created stable prostate cancer cell lines (PC-3 and 22Rv1) with either silenced (siH19) or overexpressed (oeH19) H19 levels to observe the effects on growth and invasion.
  • Epigenetic Modulation: They used GSK-J4, a small-molecule inhibitor of the histone demethylases KDM6A/UTX and KDM6B/JMJD3.
  • In Vivo Models: Immunodeficient mice were used for two types of studies:
  • Subcutaneous xenografts to measure primary tumor growth.
  • Tail-vein injections to model experimental metastasis to the lungs, bones, and liver.
  • Ex Vivo Organotypic Slice Cultures (OSCs): This is a sophisticated technique where fresh tumor tissue from 25 PCa patients was sliced and cultured in 3D, allowing the researchers to test the drug on actual human tumor architecture.
  • Molecular Analysis: Techniques included Chromatin Immunoprecipitation (ChIP) to see how proteins bind to DNA, qPCR for gene expression, and bioluminescent imaging (IVIS) to track tumors in living mice.

Datasets

The study utilized:

  • Standard Cell Lines: PC-3M-luc2 (Androgen Receptor-null) and 22Rv1-luc (expressing AR and the ARv7 variant), both engineered for bioluminescence.
  • Patient Cohort: A newly described dataset of 25 prostate cancer patients (ages 49–79) provided tissue for the OSC experiments. Clinical data including PSA levels, Gleason scores, and pathological stages are detailed in the paper (Table 1).

Key Insights and Ideas

  • The H19 Switch: H19 normally acts as a repressor. It keeps adhesion genes "off" by maintaining high levels of H3K27me3 (a repressive epigenetic mark) at their promoters. When H19 is lost, the "brakes" come off, and the cells become "stickier" and more metastatic.
  • Collective Migration is Deadlier: The study confirms that H19-silenced cells form clusters that are highly efficient at colonizing distant organs. IHC staining showed these clusters embedded in lung and bone tissue, confirming the "cohesive" phenotype.
  • Targeting the "Erasers": The researchers found that when H19 is low, histone demethylases (KDM6A and KDM6B) are recruited to the promoters of adhesion genes to "erase" the repressive marks. By using GSK-J4 to inhibit these erasers, they could effectively restore the repressive state and stop the metastatic program.
  • Androgen Independence: Crucially, this H19/adhesion circuitry appears to function regardless of whether the cancer is sensitive to androgen or has developed resistance (like the ARv7 variant), making it a potential target for late-stage, castration-resistant prostate cancer.

Key Results

  • In Vitro: Silencing H19 led to a ~2-fold increase in cell invasion and significantly higher proliferation rates.
  • In Vivo Growth: In mouse models, H19-silenced tumors grew significantly faster. Treatment with GSK-J4 restored basal growth levels, effectively neutralizing the advantage gained by H19 loss.
  • Metastasis Reduction: Mice injected with H19-silenced cells showed a high burden of bone, lung, and liver metastases. GSK-J4 treatment significantly reduced the number and size of these lesions (e.g., reducing the diameter of liver metastases).
  • Patient Tissue Response: In the ex vivo OSCs, roughly 50% of patient samples (12/25) were "J4-responders," showing a significant reduction in adhesion markers and a 1.7-fold increase in cell death following treatment.

Limitations and Future Work

  • Heterogeneity in Response: Only about half of the patient samples responded to GSK-J4. The authors acknowledge that further research is needed to identify biomarkers that can predict which patients will benefit from this specific epidrug.
  • Drug Delivery and Toxicity: While GSK-J4 showed efficacy in mice, the transition to human clinical trials requires careful evaluation of systemic toxicity and optimal delivery methods for a histone demethylase inhibitor.
  • Mechanism Specificity: While the study focuses on KDM6A/B, the epigenetic landscape is complex. Future work could explore if other chromatin modifiers are involved in the H19-mediated repression of cell adhesion.

Summary updated

Abstract

Our findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy.
BibTeX
@inproceedings{pecci2024targeting,
  author = {Valeria Pecci and Fabiola Troisi and Aurora Aiello and Sara De Martino and Angela Carlino and Vincenzo Fiorentino and Cristian Ripoli and Dante Rotili and Francesco Pierconti and Maurizio Martini and Manuela Porru and Francesco Pinto and Antonello Mai and Pier Francesco Bassi and Claudio Grassi and Carlo Gaetano and Alfredo Pontecorvi and Lidia Strigari and Antonella Farsetti and Simona Nanni},
  title = {{Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer}},
  booktitle = {Cancer},
  year = {2024},
  doi = {10.1186/s12935-024-03231-6},
}
Figure